Nitazoxanide 500mg Tablet Franchise in Ahmedabad

Anti-Asthmatic & Allergy Therapy Supplier in Mumbai

Monclip 5 Tablet Distributor in Delhi

Asthma & Respiratory Relief Tablet Franchise Opportunity in Bangalore

Pediatric Allergy & Asthma Tablet Stockist in Hyderabad
Montelukast 5mg Export & Manufacturing in Chandigarh

Home/Products /nitazoxanide-500mg-tablet

Nitanap 500 Tablet

Composition : Nitazoxanide (500mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Nitanap 500 Tablet contains Nitazoxanide 500mg, a broad-spectrum antiprotozoal and antimicrobial agent indicated for the treatment of gastrointestinal protozoal infections such as giardiasis, amoebiasis, and other parasitic infections. It helps in reducing parasite load and alleviating associated symptoms.

Nitazoxanide works by interfering with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction essential for anaerobic energy metabolism in protozoa and anaerobic bacteria, effectively eliminating the pathogen.

For distributors and healthcare suppliers, Nitanap 500 Tablet is a high-demand gastrointestinal therapy product, commonly used in hospitals, clinics, and outpatient care. The persistent prevalence of parasitic infections ensures stable and continuous market demand.

Adding Nitanap 500 Tablet to your antiprotozoal and antimicrobial therapy segment creates strong opportunities in pharmacies, hospitals, travel clinics, export markets, and third-party manufacturing. Its proven efficacy, broad therapeutic coverage, and prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.

Read More

About the Product

Nitanap 500 Tablet contains Nitazoxanide 500mg, a broad-spectrum antiprotozoal and antimicrobial agent indicated for the treatment of gastrointestinal protozoal infections such as giardiasis, amoebiasis, and other parasitic infections. It helps in reducing parasite load and alleviating associated symptoms.

Nitazoxanide works by interfering with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction essential for anaerobic energy metabolism in protozoa and anaerobic bacteria, effectively eliminating the pathogen.

For distributors and healthcare suppliers, Nitanap 500 Tablet is a high-demand gastrointestinal therapy product, commonly used in hospitals, clinics, and outpatient care. The persistent prevalence of parasitic infections ensures stable and continuous market demand.

Adding Nitanap 500 Tablet to your antiprotozoal and antimicrobial therapy segment creates strong opportunities in pharmacies, hospitals, travel clinics, export markets, and third-party manufacturing. Its proven efficacy, broad therapeutic coverage, and prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.

Common side effects may include nausea, vomiting, abdominal pain, diarrhea, headache, or urine discoloration. Rarely, allergic reactions such as rash, itching, or swelling may occur. Patients should seek medical attention if severe or persistent symptoms develop.

Nitanap 500 Tablet is indicated for the treatment of intestinal protozoal and helminthic infections, including amoebiasis, giardiasis, cryptosporidiosis, and other parasitic gastrointestinal infections, as directed by a healthcare professional.

Nitanap 500 Tablet should be taken exactly as prescribed and the full course completed to ensure effective eradication of infection. Inform your doctor if you have liver or kidney disease, or if you are pregnant or breastfeeding, before starting treatment.

Store Nitanap 500 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and ensure the blister pack is intact. Do not use the tablet beyond the expiry date printed on the packaging.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation